Antiretroviral Medication and HIV Prevention: New Steps Forward and New Questions

Mayer, Kenneth H.; Krakower, Douglas
February 2012
Annals of Internal Medicine;2/21/2012, Vol. 156 Issue 4, p312
Academic Journal
During the past 2 years, several pivotal clinical trials have proven that the use of antiretrovirals by HIV-infected and at-risk uninfected persons can decrease the probability of HIV being transmitted sexually. The initial chemoprophylaxis studies evaluated tenofovir administered topically or orally (with or without emtricitabine). However, several questions remain. Some subsequent primary prevention studies did not replicate the results of the initial studies, raising questions about differences in the behaviors of participants in each study (in particular about medication adherence), as well as whether pharmacologic or local mucosal factors might explain the variable efficacy estimates. Other antiretrovirals and delivery systems are being evaluated to maximize the efficacy of primary chemoprophylactic approaches. At present, increasing access to antiretroviral treatment globally is a priority, because expanding access to medication that can prevent morbidity and mortality is itself an important public health goal and may reasonably be expected to decrease HIV incidence. However, for treatment as prevention to be maximally effective, increases in HIV testing, health care workers, and infrastructure are needed, in addition to medications and laboratory support for clinical monitoring. A combination of approaches is needed to most quickly decrease the current trends in HIV incidence, including early diagnosis and initiation of treatment for HIV-infected persons. These approaches can be coupled with appropriately tailored interventions for populations at greatest risk for infection (for example, men who have sex with men and sex workers), including male circumcision, behavioral interventions, and chemoprophylaxis. However, a substantial gap exists between current expenditures and unmet needs, which suggests that mobilization of political will is needed for this combination approach to be successful.


Related Articles

  • Early Use of Antiretrovirals May Reduce HIV Transmission. Norman, Kayda // Applied Clinical Trials;Jun2011, Vol. 20 Issue 6, p17 

    The article discusses the findings of a study on a clinical trial known as the HPTN 052 in relation to the early use of oral antiretroviral therapy (ART). It states that the early use of ART may reduce the likelihood that a person with human immunodeficiency virus (HIV) will pass the virus to...

  • Vaginal gel may help prevent HIV.  // Contemporary Sexuality;Sep2010, Vol. 44 Issue 9, p6 

    This article reports on a study of vaginal gels that contain the antiretroviral drug tenofovir and whether they can help prevent human immunodeficiency virus (HIV).

  • Who's prepared to make PrEP work? Mascolini, Mark // Research Initiative/Treatment Action!;Winter2012, Vol. 17 Issue 2, p5 

    Tenofovir/emtricitabine (TDF/FTC) won FDA approval for preexposure prophylaxis (PrEP) after three placebo-controlled trials demonstrated that once-daily TDF/FTC lowers HIV acquisition risk in gay and bisexual men and heterosexual women and men. In the one trial that found no HIV protection with...

  • One Oral PrEP Arm Discontinued Early in VOICE Trial.  // VAX;Sep2011, Vol. 9 Issue 5, p3 

    The article reports that the clinical trial titled VOICE that was scheduled to be concluded in June 2012 was terminated in September 2011. As stated, the termination was declared when it was examined that the trial would not be able to highlight any difference between daily doses of...

  • Change in Vitamin D Levels Occurs Early after Antiretroviral Therapy Initiation and Depends on Treatment Regimen in Resource-Limited Settings. Havers, Fiona P.; Detrick, Barbara; Cardoso, Sandra W.; Berendes, Sima; Lama, Javier R.; Sugandhavesa, Patcharaphan; Mwelase, Noluthando H.; Campbell, Thomas B.; Gupta, Amita // PLoS ONE;Apr2014, Vol. 9 Issue 4, p1 

    Study Background: Vitamin D has wide-ranging effects on the immune system, and studies suggest that low serum vitamin D levels are associated with worse clinical outcomes in HIV. Recent studies have identified an interaction between antiretrovirals used to treat HIV and reduced serum vitamin D...

  • Perspectives on use of oral and vaginal antiretrovirals for HIV prevention: the VOICE-C qualitative study in Johannesburg, South Africa. van der Straten, Ariane; Stadler, Jonathan; Luecke, Ellen; Laborde, Nicole; Hartmann, Miriam; Montgomery, Elizabeth T. // Journal of the International AIDS Society;2014 Supplement 2, Vol. 17 Issue Supp 2, p1 

    Introduction: Antiretroviral (ARV)-based pre-exposure prophylaxis (PrEP) is a promising new HIV prevention strategy. However, variable levels of adherence have yielded mixed results across several PrEP trials and populations. It is not clear how taking ARV - traditionally used for HIV treatment...

  • Antiretroviral use in children safe without routine lab monitoring.  // Reactions Weekly;3/16/2013, Issue 1444, p1 

    The article reports that clinical trials have shown antiretroviral use in children are safe without routine laboratory monitoring.

  • Africa: Problems Getting Antiretrovirals for Trials.  // AIDS Treatment News;5/30/2003, Issue 391, p5 

    Reports on difficulties of getting antiretrovirals for trials in developing countries. Claim that the U.S. wants patients be offered continued treatment after the trial; Consensus that researchers must offer continued treatment after a trial among African countries.

  • Adherence to Antiretroviral Prophylaxis for HIV Prevention: A Substudy Cohort within a Clinical Trial of Serodiscordant Couples in East Africa. Haberer, Jessica E.; Baeten, Jared M.; Campbell, James; Wangisi, Jonathan; Katabira, Elly; Ronald, Allan; Tumwesigye, Elioda; Psaros, Christina; Safren, Steven A.; Ware, Norma C.; Thomas, Katherine K.; Donnell, Deborah; Krows, Meighan; Kidoguchi, Lara; Celum, Connie; Bangsberg, David R. // PLoS Medicine;Sep2013, Vol. 10 Issue 9, p1 

    : Jessica Haberer and colleagues investigate the association between high adherence to antiretroviral pre-exposure prophylaxis and HIV transmission in a substudy of serodiscordant couples participating in a clinical trial. Please see later in the article for the Editors' Summary


Other Topics